Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Evaluate the efficacy and tolerability of sorafenib in RCC patients underwent to metastasectomy

Phase 2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Niacinamide
Sorafenib